Prostate Cancer Evaluation of TaRgets in Genito Urinary Screening Program (PETRUS)
Primary Purpose
Metastatic Castration Resistant Prostate Cancer Patients
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
metastasis biopsy
Sponsored by
About this trial
This is an interventional diagnostic trial for Metastatic Castration Resistant Prostate Cancer Patients
Eligibility Criteria
Inclusion Criteria:
- Prostate Cancer patients
- Castration Resistant
- Prostatic tissue available
- Metastasis which may be biopsied
Exclusion Criteria:
Sites / Locations
- Institut Gustave Roussy
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
experimental
Arm Description
metastasis biopsy
Outcomes
Primary Outcome Measures
Biomarker
success to evaluate at least one molecular analysis in tumor tissues (prostate and/or metastatic site) AND in CTC
Secondary Outcome Measures
Full Information
NCT ID
NCT01786031
First Posted
December 3, 2012
Last Updated
February 5, 2016
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
1. Study Identification
Unique Protocol Identification Number
NCT01786031
Brief Title
Prostate Cancer Evaluation of TaRgets in Genito Urinary Screening Program
Acronym
PETRUS
Official Title
Prostate Cancer Evaluation of TaRgets in Genito Urinary Screening Program
Study Type
Interventional
2. Study Status
Record Verification Date
February 2016
Overall Recruitment Status
Completed
Study Start Date
December 2012 (undefined)
Primary Completion Date
January 2015 (Actual)
Study Completion Date
January 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Toward personalised treatment in early metastatic prostate cancer based on the assessment of biomarkers in cancer tissue samples and circulating tumour cells.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metastatic Castration Resistant Prostate Cancer Patients
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
55 (Actual)
8. Arms, Groups, and Interventions
Arm Title
experimental
Arm Type
Experimental
Arm Description
metastasis biopsy
Intervention Type
Other
Intervention Name(s)
metastasis biopsy
Primary Outcome Measure Information:
Title
Biomarker
Description
success to evaluate at least one molecular analysis in tumor tissues (prostate and/or metastatic site) AND in CTC
Time Frame
assessed at the end of recruitment, up to 2 years
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Prostate Cancer patients
Castration Resistant
Prostatic tissue available
Metastasis which may be biopsied
Exclusion Criteria:
Facility Information:
Facility Name
Institut Gustave Roussy
City
Villejuif
State/Province
Val de Marne
ZIP/Postal Code
94805
Country
France
12. IPD Sharing Statement
Citations:
PubMed Identifier
26923772
Citation
Lindsay CR, Le Moulec S, Billiot F, Loriot Y, Ngo-Camus M, Vielh P, Fizazi K, Massard C, Farace F. Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer. BMC Cancer. 2016 Feb 29;16:168. doi: 10.1186/s12885-016-2192-6.
Results Reference
derived
Learn more about this trial
Prostate Cancer Evaluation of TaRgets in Genito Urinary Screening Program
We'll reach out to this number within 24 hrs